Payment overview · 2025
General Payments
$3,193.04
201 reported records · 18 companies
Healthcare provider profile · identity verified
Duc Hong Phan, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1083946693
Verified facts
What the public records show
CMS Open Payments records show Duc Hong Phan, M.D received $3,193.04 in general payments during 2025 across 201 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Otezla, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 345 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 521 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $592.63 | 18.6% | 23 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $336.73 | 10.6% | 27 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $326.34 | 10.2% | 27 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $322.70 | 10.1% | 31 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $297.34 | 9.3% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $276.88 | 8.7% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $231.26 | 7.2% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $180.84 | 5.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $139.56 | 4.4% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $136.31 | 4.3% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $83.11 | 2.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.97 | 2.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.03 | 2.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.26 | 1.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.16 | 0.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.75 | 0.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.19 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.98 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,193.04 | 201 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $574.92 | 22 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $336.73 | 27 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $276.88 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $270.21 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $262.91 | 23 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $262.91 | 23 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $257.28 | 26 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $252.50 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $252.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $249.08 | 17 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $225.94 | 24 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.65 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $196.07 | 8 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $180.84 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $139.56 | 10 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $136.31 | 12 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $132.06 | 10 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $99.69 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.43 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.15 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.86 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.56 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.56 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 66 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 128 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 345 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 175 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 611 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 77 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 318 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 312 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 521 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 189 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
128 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
318 | 125 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
183 | 104 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
345 | 116 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 23 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
611 | 176 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
123 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
66 | 66 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
79 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
189 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
611 | 176 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
102 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
312 | 81 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
521 | 123 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
175 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1869 | 724 |
| Losartan Potassium | Losartan Potassium | 1396 | 517 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1383 | 511 |
| Metformin Hcl | Metformin Hcl | 1269 | 468 |
| Vascepa | Icosapent Ethyl | 1172 | 333 |
| Fluticasone Propionate | Fluticasone Propionate | 1017 | 414 |
| Pioglitazone Hcl | Pioglitazone Hcl | 970 | 344 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 903 | 409 |
| Metoprolol Succinate | Metoprolol Succinate | 877 | 356 |
| Amoxicillin | Amoxicillin | 867 | 458 |
| Gabapentin | Gabapentin | 861 | 360 |
| Diclofenac Sodium | Diclofenac Sodium | 826 | 325 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 792 | 359 |
| Famotidine | Famotidine | 777 | 314 |
| Amlodipine Besylate | Amlodipine Besylate | 772 | 322 |
| Tamsulosin Hcl | Tamsulosin Hcl | 716 | 303 |
| Alendronate Sodium | Alendronate Sodium | 709 | 261 |
| Pravastatin Sodium | Pravastatin Sodium | 670 | 247 |
| Jardiance | Empagliflozin | 611 | 176 |
| Rybelsus | Semaglutide | 521 | 123 |
| Clopidogrel | Clopidogrel Bisulfate | 513 | 206 |
| Baclofen | Baclofen | 492 | 255 |
| Donepezil Hcl | Donepezil Hcl | 480 | 208 |
| Naproxen | Naproxen | 469 | 215 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 466 | 146 |
| Omeprazole | Omeprazole | 459 | 186 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 445 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 440 | 214 |
| Meclizine Hcl | Meclizine Hcl | 385 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 136 |
| Tramadol Hcl | Tramadol Hcl | 383 | 119 |
| Alprazolam | Alprazolam | 379 | 89 |
| Simvastatin | Simvastatin | 375 | 132 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 372 | 143 |
| Azelastine Hcl | Azelastine Hcl | 370 | 147 |
| Clobetasol Propionate | Clobetasol Propionate | 364 | 121 |
| Finasteride | Finasteride | 364 | 144 |
| Metformin Hcl Er | Metformin Hcl | 355 | 129 |
| Azithromycin | Azithromycin | 350 | 189 |
| Ibuprofen | Ibuprofen | 347 | 204 |
| Loperamide | Loperamide Hcl | 347 | 199 |
| Carvedilol | Carvedilol | 346 | 143 |
| Farxiga | Dapagliflozin Propanediol | 345 | 116 |
| Lisinopril | Lisinopril | 331 | 128 |
| Montelukast Sodium | Montelukast Sodium | 324 | 131 |
| Lidocaine | Lidocaine | 320 | 101 |
| Linzess | Linaclotide | 318 | 125 |
| Tradjenta | Linagliptin | 317 | 71 |
| Ozempic | Semaglutide | 312 | 81 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 291 | 134 |
| Trazodone Hcl | Trazodone Hcl | 288 | 130 |
| Mirtazapine | Mirtazapine | 287 | 122 |
| Meloxicam | Meloxicam | 274 | 165 |
| Prednisone | Prednisone | 268 | 181 |
| Januvia | Sitagliptin Phosphate | 261 | 66 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 244 | 100 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 243 | 91 |
| Allopurinol | Allopurinol | 231 | 103 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 230 | 81 |
| Celecoxib | Celecoxib | 221 | 78 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 217 | 134 |
| Furosemide | Furosemide | 209 | 99 |
| Mupirocin | Mupirocin | 202 | 112 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 199 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 47 |
| Cimetidine | Cimetidine | 191 | 85 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 189 | 65 |
| Glyxambi | Empagliflozin/Linagliptin | 187 | 49 |
| Ztlido | Lidocaine | 184 | 62 |
| Prolia | Denosumab | 183 | 104 |
| Colchicine | Colchicine | 182 | 77 |
| Mometasone Furoate | Mometasone Furoate | 179 | 66 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 178 | 54 |
| Pregabalin | Pregabalin | 177 | 48 |
| Cephalexin | Cephalexin | 175 | 120 |
| Gemtesa | Vibegron | 175 | 59 |
| Restasis | Cyclosporine | 174 | 54 |
| Glipizide Er | Glipizide | 158 | 49 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 157 | 41 |
| Myrbetriq | Mirabegron | 155 | 46 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 154 | 35 |
| Atenolol | Atenolol | 153 | 57 |
| Sucralfate | Sucralfate | 152 | 51 |
| Ezetimibe | Ezetimibe | 143 | 53 |
| Hydrocortisone | Hydrocortisone | 139 | 64 |
| Methylprednisolone | Methylprednisolone | 134 | 90 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 132 | 49 |
| Dicyclomine Hcl | Dicyclomine Hcl | 130 | 54 |
| Creon | Lipase/Protease/Amylase | 128 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 127 | 58 |
| Megestrol Acetate | Megestrol Acetate | 127 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 125 | 83 |
| Ketoconazole | Ketoconazole | 124 | 49 |
| Vemlidy | Tenofovir Alafenamide | 123 | 16 |
| Clonidine Hcl | Clonidine Hcl | 121 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 43 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 117 | 45 |
| Dexlansoprazole Dr | Dexlansoprazole | 117 | 30 |
| Xarelto | Rivaroxaban | 117 | 31 |
| Nitroglycerin | Nitroglycerin | 116 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 22 |
| Ammonium Lactate | Ammonium Lactate | 107 | 48 |
| Nifedipine Er | Nifedipine | 105 | 44 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 104 | 36 |
| Mounjaro | Tirzepatide | 104 | 28 |
| Trulicity | Dulaglutide | 102 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 46 |
| Lactulose | Lactulose | 100 | 47 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 100 | 27 |
| Dutasteride | Dutasteride | 99 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 97 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 39 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 96 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 63 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 27 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 93 | 26 |
| Icosapent Ethyl | Icosapent Ethyl | 92 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 36 |
| Valacyclovir | Valacyclovir Hcl | 89 | 41 |
| Sertraline Hcl | Sertraline Hcl | 88 | 36 |
| Valsartan | Valsartan | 88 | 40 |
| Acyclovir | Acyclovir | 87 | 42 |
| Propranolol Hcl | Propranolol Hcl | 86 | 34 |
| Fenofibrate | Fenofibrate | 85 | 23 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 84 | 31 |
| Latanoprost | Latanoprost | 82 | 24 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 80 | 31 |
| Levofloxacin | Levofloxacin | 79 | 54 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 79 | 48 |
| Sildenafil Citrate | Sildenafil Citrate | 79 | 21 |
| Kerendia | Finerenone | 77 | 22 |
| Procto-Med Hc | Hydrocortisone | 77 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 24 |
| Potassium Chloride | Potassium Chloride | 76 | 32 |
| Prednisolone Acetate | Prednisolone Acetate | 75 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 33 |
| Memantine Hcl | Memantine Hcl | 73 | 28 |
| Eliquis | Apixaban | 71 | 23 |
| Clotrimazole | Clotrimazole | 69 | 33 |
| Irbesartan | Irbesartan | 69 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 67 | 24 |
| Nystatin | Nystatin | 67 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 66 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 66 | 66 |
| Fluocinonide | Fluocinonide | 66 | 23 |
| Glimepiride | Glimepiride | 66 | 28 |
| Lansoprazole | Lansoprazole | 66 | 20 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 66 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 65 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 65 | 23 |
| Ranolazine Er | Ranolazine | 63 | 25 |
| Glipizide | Glipizide | 60 | 22 |
| Ibu | Ibuprofen | 60 | 36 |
| Olopatadine Hcl | Olopatadine Hcl | 60 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 24 |
| Carisoprodol | Carisoprodol | 57 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 57 | 34 |
| Buspirone Hcl | Buspirone Hcl | 56 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 56 | 32 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 23 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 55 | 34 |
| Gentamicin Sulfate | Gentamicin Sulfate | 55 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 39 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 55 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 54 | 17 |
| Nabumetone | Nabumetone | 54 | 28 |
| Scopolamine | Scopolamine | 54 | 25 |
| Estradiol | Estradiol | 52 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 51 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 23 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 51 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 49 | 19 |
| Cromolyn Sodium | Cromolyn Sodium | 49 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 48 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 20 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 46 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 12 |
| Fluconazole | Fluconazole | 45 | 26 |
| Prednisolone | Prednisolone | 45 | 36 |
| Enalapril Maleate | Enalapril Maleate | 44 | 14 |
| Erythromycin | Erythromycin Base | 44 | 18 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 43 | 17 |
| Halobetasol Propionate | Halobetasol Propionate | 43 | 17 |
| Lubiprostone | Lubiprostone | 43 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 40 | 18 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 39 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 39 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 16 |
| Xiidra | Lifitegrast | 38 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 15 |
| Desoximetasone | Desoximetasone | 37 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 27 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | 12 |
| Cefdinir | Cefdinir | 35 | 30 |
| Desonide | Desonide | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 16 |
| Promethazine Hcl | Promethazine Hcl | 34 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 12 |
| Combigan | Brimonidine Tartrate/Timolol | 33 | suppressed |
| Dexamethasone | Dexamethasone | 33 | 15 |
| Gemfibrozil | Gemfibrozil | 33 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 14 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 32 | 21 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 28 |
| Difluprednate | Difluprednate | 30 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Ssd | Silver Sulfadiazine | 28 | 13 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 27 | 16 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Lumigan | Bimatoprost | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 25 | suppressed |
| Fluorometholone | Fluorometholone | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Dexilant | Dexlansoprazole | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | 12 |
| Repaglinide | Repaglinide | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Otezla | Apremilast | 20 | suppressed |
| Pimecrolimus | Pimecrolimus | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Tretinoin | Tretinoin | 19 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Entecavir | Entecavir | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Proctozone-Hc | Hydrocortisone | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Aripiprazole Odt | Aripiprazole | 11 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Podofilox | Podofilox | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,193.04 · 201 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, Kerendia, Korlym, LINZESS, LOKELMA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error